Aripiprazole/sertraline

Aripiprazole/sertraline
Combination of
AripiprazoleAtypical antipsychotic
SertralineSelective serotonin reuptake inhibitor
Clinical data
Other namesASC-01
Routes of
administration		By mouth
Legal status
Legal status

Aripiprazole/sertraline (developmental code name ASC-01) is a combination formulation of aripiprazole (Abilify), an atypical antipsychotic, and sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), which was under development by Otsuka Pharmaceutical for the treatment of major depressive disorder (MDD).[1] It combines serotonin reuptake inhibition from sertraline and modulation of dopamine and serotonin receptors from aripiprazole.[1][2] In July 2017, it was in preregistration in Japan for the treatment of MDD.[1] However, in September 2018, the regulatory submission in Japan for MDD was withdrawn.[3]

See also

References

  1. 1 2 3 "Aripiprazole/sertraline - Otsuka Pharmaceutical". AdisInsight. Springer Nature Switzerland AG.
  2. ↑ Kamdijima K, Kimura M, Kuwahara K, Kitayama Y, Tadori Y (August 2018). "Randomized, double-blind comparison of aripiprazole/sertraline combination and placebo/sertraline combination in patients with major depressive disorder". Psychiatry and Clinical Neurosciences. 72 (8): 591–601. doi:10.1111/pcn.12663. PMID 29660207. S2CID 4958169.
  3. ↑ "Aripiprazole/sertraline - Otsuka Pharmaceutical - AdisInsight". adisinsight.springer.com.



This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.